Medihoney® Derma Cream Treatment for Mild to Moderate Atopic Dermatitis in Children Study

• Status: Completed
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

A randomized, open-label trial comparing Medihoney Derma Cream to Hydrocortisone 1% cream. Children between the ages of 2-18 years old diagnosed with mild to moderate atopic dermatitis with an IGA (Investigator Global Assessment) score of 2-3, and a BSA (Body Surface Area) score of 1%-10% were included.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Soroka University Medical Center
• Treatments: Hydrocortisone

Criteria

Inclusion Criteria:

• 2-18 years old

• mild to moderate atopic dermatitis

• an IGA score of 2-3

• BSA score of 1%-10%.

Exclusion Criteria:

• participation in any clinical trial less than 28 days before the enrollment

• AD-related systemic therapy or phototherapy within 28 days prior to the enrollment

• topical corticosteroids, calcineurin inhibitors, or PDE4 inhibitors use within 7 days prior to the enrollment